Dn B Asset Management As Vertex Pharmaceuticals Inc Transaction History

Dn B Asset Management As

$19.9 Billion
Q2 2024

A detailed history of Dn B Asset Management As transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Dn B Asset Management As holds 166,722 shares of VRTX stock, worth $82.7 Million. This represents 0.39% of its overall portfolio holdings.

Number of Shares

166,722

Previous 191,250 12.83%

Holding current value

$82.7 Million

Previous $79.9 Million 2.25%

% of portfolio

0.39%

Previous 0.44%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 05, 2024	SELL	$392.81 - $485.53 $9.63 Million - $11.9 Million	-24,528 Reduced 12.83%	166,722 $78.1 Million
Q1 2024 Apr 12, 2024	SELL	$407.69 - $446.08 $2.92 Million - $3.2 Million	-7,168 Reduced 3.61%	191,250 $79.9 Million
Q4 2023 Jan 04, 2024	BUY	$343.0 - $410.68 $2.13 Million - $2.55 Million	6,211 Added 3.23%	198,418 $80.7 Million
Q3 2023 Oct 13, 2023	SELL	$338.18 - $362.46 $5.55 Million - $5.94 Million	-16,398 Reduced 7.86%	192,207 $66.8 Million
Q2 2023 Jul 06, 2023	SELL	$314.42 - $351.91 $23.6 Million - $26.4 Million	-75,042 Reduced 26.46%	208,605 $73.4 Million

Q1 2023 Apr 20, 2023	SELL	$283.23 - $323.1 $4.56 Million - $5.21 Million	-16,116 Reduced 5.38%	283,647 $89.4 Million
Q4 2022 Jan 12, 2023	SELL	$285.76 - $321.48 $4.63 Million - $5.21 Million	-16,219 Reduced 5.13%	299,763 $86.6 Billion
Q3 2022 Oct 11, 2022	SELL	$273.83 - $305.53 $8 Million - $8.93 Million	-29,221 Reduced 8.46%	315,982 $91.5 Million
Q2 2022 Jul 08, 2022	SELL	$234.96 - $292.55 $1.47 Million - $1.84 Million	-6,275 Reduced 1.79%	345,203 $97.3 Billion
Q1 2022 Apr 08, 2022	SELL	$221.42 - $260.97 $30.2 Million - $35.6 Million	-136,417 Reduced 27.96%	351,478 $91.7 Million
Q4 2021 Jan 12, 2022	SELL	$177.01 - $223.45 $3.9 Million - $4.92 Million	-22,007 Reduced 4.32%	487,895 $107 Million
Q3 2021 Oct 15, 2021	BUY	$181.39 - $202.99 $15.7 Million - $17.6 Million	86,593 Added 20.46%	509,902 $92.5 Million
Q2 2021 Jul 06, 2021	BUY	$187.49 - $221.1 $65.5 Million - $77.3 Million	349,530 Added 473.75%	423,309 $85.4 Billion
Q1 2021 Apr 15, 2021	BUY	$207.02 - $241.31 $7.31 Million - $8.52 Million	35,326 Added 91.87%	73,779 $15.9 Million
Q4 2020 Jan 19, 2021	BUY	$207.01 - $276.09 $769,663 - $1.03 Million	3,718 Added 10.7%	38,453 $9.09 Million
Q3 2020 Oct 14, 2020	BUY	$255.65 - $303.1 $658,298 - $780,482	2,575 Added 8.01%	34,735 $9.45 Million
Q2 2020 Jul 08, 2020	BUY	$225.48 - $295.8 $1.19 Million - $1.55 Million	5,256 Added 19.54%	32,160 $9.34 Billion
Q1 2020 Apr 17, 2020	SELL	$199.77 - $247.81 $1.05 Million - $1.3 Million	-5,238 Reduced 16.3%	26,904 $6.4 Million
Q4 2019 Jan 13, 2020	BUY	$166.71 - $223.91 $733,023 - $984,532	4,397 Added 15.85%	32,142 $7.04 Million
Q3 2019 Oct 16, 2019	BUY	$166.23 - $187.09 $323,151 - $363,702	1,944 Added 7.53%	27,745 $4.7 Million
Q2 2019 Jul 08, 2019	SELL	$164.61 - $190.37 $269,137 - $311,254	-1,635 Reduced 5.96%	25,801 $0
Q1 2019 Apr 11, 2019	SELL	$163.73 - $194.7 $504,943 - $600,454	-3,084 Reduced 10.1%	27,436 $0
Q4 2018 Jan 15, 2019	SELL	$151.91 - $192.21 $319,618 - $404,409	-2,104 Reduced 6.45%	30,520 $5.06 Million
Q3 2018 Oct 10, 2018	BUY	$167.73 - $192.74 $175,110 - $201,220	1,044 Added 3.31%	32,624 $0
Q2 2018 Jul 06, 2018	BUY	$145.72 - $169.96 $349,728 - $407,904	2,400 Added 8.22%	31,580 $0
Q1 2018 Apr 11, 2018	BUY	$151.6 - $177.13 $439,640 - $513,677	2,900 Added 11.04%	29,180 $0
Q4 2017 Jan 10, 2018	BUY	$137.28 - $155.55 $82,368 - $93,330	600 Added 2.34%	26,280 $0
Q3 2017 Oct 11, 2017	BUY	$148.13 - $162.24 $3.8 Million - $4.17 Million	25,680	25,680 $0

Others Institutions Holding VRTX

# of Institutions

1,639

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $127B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dn B Asset Management As, based on Form 13F filings with the SEC.

News

Stay updated on Dn B Asset Management As with notifications on news.

Account

Dn B Asset Management As Vertex Pharmaceuticals Inc Transaction History